Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome

Canaccord Believes Zoetis Could Bid For Idexx Laboratories


In a report published Monday, Canaccord Genuity analyst Mark Massaro detailed an investor meeting with IDEXX Laboratories, Inc. (NASDAQ: IDXX)'s management which reaffirmed the analyst's "positive trajectory" of the company's new product launches.

Massaro noted that Idexx's survey data indicates 25 percent of VCA Antech customers expressed an interest in switching to Idexx's reference lab or purchasing SDMA, its early diagnosis for chronic kidney disease. The analyst also noted that the company holds IP for SDMA which took years to develop, thus the company holds an advantage as barriers to entry are high.

Massaro said that the company's management team also acknowledged that it underestimated the degree to which distributors would react to going all-direct and the impact that Zoetis Inc (NYSE: ZTS) and Abaxis Inc (NASDAQ: ABAX) would have in their new rapid test launches. According to the analyst, Idexx is "taking competitive concerns seriously" and implementing necessary steps to overcome these pressures.

Massaro also stated that Idexx's management team declined to comment on recent reports that Zoetis is interest in scaling up its animal health diagnostic business. In fact, the analyst argued that Zoetis could make a bid for Idexx.

"Idexx's head of sales formerly worked at Zoetis, and at a $24 billion market cap with approximately $600 million of cash on the balance sheet and operating in a low-interest-rate environment, coupled with the fact that Zoetis successfully dropped its distributors and favors the "all direct model," we think Zoetis could make a bid for Idexx," Massaro wrote.

Bottom line, Massaro suggested that the possibility of Zoetis acquiring Idexx, along with a new share buyback authorization and the CEO recently buying stock indicates the risk to reward profile on shares is to the upside.

Shares remain Buy rated with an unchanged $80 price target.

Latest Ratings for ZTS

Jun 2019Initiates Coverage OnOverweight
May 2019MaintainsMarket Perform
May 2019DowngradesBuyHold

View More Analyst Ratings for ZTS
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity Mark Massaro SDMA vca antechAnalyst Color Analyst Ratings


Related Articles (ABAX + IDXX)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Global Hunter Initiates KMG Chemicals With Neutral

KeyBanc Initiates Babcock & Wilcox With Overweight